Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Liver Transplant Provider Perspectives on Posttransplant Management of Alcohol Use Disorder
Cote, Maria P. , Cloonan, Daniel , Li, Sienna, Razak, Shahaan S. , Singh, Ruby , Coe, Taylor M. , Zimbrean, Paula C. , Andrews, Sarah R., Ivkovic, Ana, Bartels, Stephen J. , Bethea, Emily D. , Yeh, Heidi , Dageforde, Leigh Anne , Bartels, Stephen , Chadha, Ryan , Bethea, Emily , Yeh, Heidi , Lim, Nicholas , Chadha, Ryan , Lim, Nicholas

Transplantation Direct | March 11, 2025 | Volume: 11 | Issue: 4 | Pages: e1766

10.1097/txd.0000000000001766 | PMID 40078821 Get It

Background. Liver transplantation (LT) is the standard treatment for liver failure secondary to alcohol-associated liver disease, but limited literature and best practices exist for post-LT treatment of alcohol use disorder (AUD). This study explores current AUD management practices and providers’ perceived barriers to effective post-LT AUD management. Methods. A 45-item survey on post-LT AUD treatment practices was distributed to members of the American Society of Transplant Surgeons, the Association of Consult/Liaison Psychiatry Transplant Special Interest Group, and both the American Society of Transplantation’s Liver and Intestine Community of Practice and Psychosocial and Ethics Community of Practice discussion boards, between December 2021 and April 2022. Univariate analysis of categorical variables was performed using the chi-square test. Data were analyzed using center volume tertiles, country region, and provider professional activity. Results. Two hundred thirty-two respondents from 70 LT centers across all 11 United Network for Organ Sharing regions completed the survey. Half of the them were attending physicians and 16.4% were nurse coordinators. Most centers (84%) aimed for alcohol abstinence for all post-LT patients. Perceived barriers to AUD treatment efficacy included ongoing desire to drink (18%), denial about alcohol misuse (14.9%), and lack of posttransplant support (14%). Additionally, 62.1% of centers had no policy for prescribing medication-assisted therapy to treat AUD, and 32.7% of centers reported no center-level changes in AUD care. Providers identified primary needs as hiring additional mental health professionals (30.8%), dedicating specific staff to AUD care (24.7%), and standardizing psychiatric/psychological care in transplant clinics (17.2%). Conclusions. Despite the increasing volume of LT for alcohol-associated liver disease, significant perceived barriers to effective AUD treatment remain.
Free‐breathing hepatic 2D magnetic resonance elastography
Li, Jiahui , Chen, Jie , Glaser, Kevin J. , Yin, Ziying , Le, Yuan , Shah, Vijay H. , Obrzut, Marzanna, Yin, Ziying , Le, Yuan , Manduca, A , Ehman, Richard , Li, Jiahui , Obrzut, Marzanna , Dzyubak, Bogdan , Chen, Jun , Allen, Alina M. , Venkatesh, Sudhakar K. , Manduca, Armando , Ehman, Richard L. , Yin, Meng

Magnetic Resonance in Medicine | March 11, 2025 | Volume: 93 | Issue: 6 | Pages: 2434-2443

10.1002/mrm.30483 | PMID 40033890 Get It

Abstract Purpose To evaluate the test–retest repeatability of a rapid, free‐breathing two‐dimensional (2D) MR elastography (MRE) technique and to assess the reliability of the liver‐stiffness measurements compared with conventional breath‐hold MREs. Methods Fifteen and 115 participants were enrolled in the technical repeatability and measurement equivalence assessment cohorts, respectively. All participants underwent rapid free‐breathing and conventional breath‐hold 2D MRE (twice in repeatability cohort) on 1.5T scanners. Both methods have four phase offsets over one harmonic motion cycle at 60 Hz; one and 10 cycles were collected and processed in breath‐hold and free‐breathing MREs, respectively. The liver stiffness measurements of free‐breathing (LS F ) and breath‐hold MRE (LS B ) were calculated from manually drawn regions of interest. The repeatability coefficients and Spearman correlation were used to assess technical repeatability and measurement agreement between LS F and LS B . Univariable and multivariable linear regressions were performed to identify potential influencing factors, including age, sex, body mass index, and fat fraction, in the measurement agreement between LS B and LS F . Results The repeatability coefficient of free‐breathing 2D MRE is comparable to breath‐hold MRE (LS F : 20.8%, LS B : 20.4%). LS F showed a strong agreement and significant correlation with LS B (LS F = 1.01 × LS B , ρ = 0.94, p < 0.001). The measurement agreement between LS F and LS B was only significantly affected by sex ( p = 0.047) after adjusting for confounding factors of age, body mass index, and fat fraction. Conclusions The nongated, free‐breathing, multislice 2D MRE technique can provide reliable liver stiffness measurements compared with conventional breath‐hold 2D MRE. It could provide a comfortable alternative method with reliable liver stiffness measurements for patients who have difficulty in suspending respiration.
Longitudinal Outcomes in Pi*MZ Alpha-1 Antitrypsin–Deficient Individuals with Tobacco Smoking History from the SPIROMICS Cohort
Barjaktarević, Igor , Hixson, Roxana, Zhuang, Zian , Buhr, Russell G. , Tejwani, Vickram , Barr, R. Graham, Bateman, Lori A. , Bhatt, Surya P. , Bleecker, Eugene R. , Cooper, Christopher B., Fortis, Spyridon , Hansel, Nadia N. , Hoffman, Eric A. , Martinez, Fernando J., Meyers, Deborah A., Paine, Robert, Pirozzi, C.S. , Sandhaus, Robert A. , Tashkin, Donald P., Wells, J. Michael , Woodruff, Prescott G. , Ortega, Victor E. , Drummond, M Bradley , Fortis, Spyridon , Hoffman, Eric A , Wells, J Michael , Barjaktarevic, Igor , Buhr, Russell G , Bhatt, Surya P , Barr, R. Graham, Curtis, Jeffrey L. , Drummond, Michael , Ghosh, Auyon , Han, MeiLan King , Ohar, Jill , Meyers, Deborah A. , Strange, Charlie

Annals of the American Thoracic Society | March 11, 2025 | Volume: 22 | Issue: 7 | Pages: 998-1008

10.1513/annalsats.202411-1209oc | PMID 40068143 Get It

Abstract Rationale Reliable data about the natural history of lung function decline in alpha-1 antitrypsin (AAT)-deficient Pi*MZ heterozygotes is largely missing. Objectives We hypothesized that, in adults with a tobacco smoking history, lung function deteriorates faster in Pi*MZ compared with the Pi*MM genotype. Methods We identified 1,856 Pi*MM and 79 Pi*MZ participants with ⩾20 pack-years tobacco smoking history from the SPIROMICS (Subpopulations and Intermediate Outcomes Measures in COPD Study) cohort by DNA sequencing and followed them over a median of 4.8 years, comparing radiographic and clinical characteristics between the two groups over time using regression models. Results Adjusted for age, sex, race, smoking pack-year history, and smoking status, Pi*MZ participants had a lower baseline percent predicted forced expiratory volume in 1 second (FEV1) (65.4% vs. 75.1%; difference 95% confidence interval [CI], −15.4% to −3.9%), more radiographic emphysema (&lt;−950 Hounsfield units%, 12.9% vs. 7.8%; difference 95% CI, 2.8% to 7.5%), and nonsignificantly lower lung density. In the longitudinal analysis, the FEV1 annual rate of decline was similar in both groups over the course of the study (−34.5 ml/yr vs. −34.6 ml/yr for Pi*MZ and Pi*MM; difference 95% CI, −16.9 to 17.1 ml/yr). There were no significant differences between Pi*MZ and Pi*MM individuals in the annualized change in lung density, emphysema, patient-reported outcomes, exacerbations, or survival. The proportion with faster FEV1 decline (annual loss ⩾40 ml) was similar in Pi*MZ and Pi*MM groups. In both groups, faster FEV1 decline was associated with more air trapping and small airway disease at baseline. In Pi*MZ only, faster decline was associated with higher blood eosinophil counts (310 vs. 220 cells/μl; difference 95% CI, 30 to 140 cells/μl). In the subgroup analysis limited to a small number of currently smoking participants, no significant differences in longitudinal outcomes were found. Conclusions Despite a lower FEV1 and more emphysema at enrollment, the longitudinal analysis did not demonstrate significantly greater lung function decline or lung density loss in Pi*MZ compared with Pi*MM participants with tobacco smoking history. Limited sample size and duration of longitudinal follow-up constrain generalizability of our findings, thus prohibiting the conclusion that longitudinal trajectories did not differ between these groups. However, our results may suggest that earlier life events could be responsible for more extensive lung disease at enrollment in Pi*MZ compared with Pi*MM tobacco-exposed individuals.
A systematic review and meta-analysis of the response to placebo in clinical trials of inclusion body myositis
Naddaf, Elie , Dimachkie, Mazen M. , Benveniste, Olivier, Mandrekar, Jay , Murad, Mohammed , Naddaf, Elie , Dimachkie, Mazen M , Skolka, Michael P , Prokop, Larry J. , Hogrel, Jean‐Yves , Benvéniste, Olivier , Wang, Zhen , West, Colin P.

Rheumatology | March 11, 2025 | Volume: 64 | Issue: 7 | Pages: 4125-4132

10.1093/rheumatology/keaf146 | PMID 40085004 Get It

Abstract Objectives IBM is characterized by slowly progressive muscle weakness making it challenging to detect significant changes in weakness during a clinical trial. Trial participants receiving placebo may behave differently from in natural history studies. We aimed to quantify the change in muscle strength and IBM Functional Rating Scale (IBMFRS) of IBM patients receiving placebo during clinical trials. Methods Several databases were searched. Randomized, double-blinded, placebo-controlled trials without treatment intervention on the placebo group were included. Standardized mean differences (SMD) for change in muscle strength and mean differences for IBMFRS were used to calculate pooled effects, using DerSimonian-Laird continuous random effect models. Meta-regression determined change in muscle strength. Heterogeneity was evaluated using the I2 indicator. Results Eleven eligible trials were identified with 257 participants receiving placebo and a low risk of bias per the Cochrane Collaboration Risk of Bias 2 (RoB2) tool. Participants receiving placebo on average had a measurable decline in muscle strength with a mean effect size of –0.398 (95% CI –0.652, –0.144) (P = 0.002). SMD changed by –0.009 (–0.016, –0.002) points per week (P = 0.015). Manual muscle testing was associated with higher heterogeneity (I2 = 67.68%) compared with quantitative muscle testing (I2 = 0%). Only three studies reported IBMFRS results. The pooled change in IBMFRS at 12 months was –2.189 points (–3.893, –0.485) on this 0 to 40-point scale (P = 0.012), with relatively high heterogeneity. Conclusion Participants with IBM displayed a measurable decline in their muscle strength and IBMFRS during clinical trials, in keeping with the disease’s slowly progressive nature. These estimates can inform sample size calculations in future studies.
Gluten‐free schooling: Navigating challenges and triumphs for children with celiac disease
Weisbrod, Vanessa , Khavari, Nasim, Absah, Imad , Mallon, Danny, Raber, Catherine , Badalyan, Vahe , Shull, Mary , Dunn, Ashley R., Wren, Anava, Mardini, Farah, Fahey, Lisa M. , Ediger, Tracy , Leonard, Maureen M. , López-Rivera, Javier A. , Jericho, Hilary , Jericho, Hilary , Weisbrod, Vanessa , Lee, Dale Young , Verma, Ritu , Dunn, Ashley, Silvester, Jocelyn A.

JPGN Reports | March 11, 2025 | Volume: 6 | Issue: 2 | Pages: 99-106

10.1002/jpr3.70013 | PMID 40386317 Get It

ABSTRACTObjectivesCeliac disease (CeD), an autoimmune disorder triggered by gluten ingestion, induces intestinal inflammation and varied symptoms. Treatment entails a strict gluten‐free diet (GFD), posing challenges for students, especially in schools with limited food choices. Nonadherence worsens symptoms, yet research on CeD's impact on students is scarce.MethodsThe CeliacKIDS study, conducted across 11 United States academic medical centers, evaluated gluten exposure risk in pediatric CeD patients via a cross‐sectional survey from August 2020 to August 2021. Participants recruited from treating institutions were approved by respective Institutional Review Boards.ResultsOne hundred and sixty children aged 5–18 (65% female, 34% male, 1% other) participated. Only 12% had GF food options at school, 31% brought their own for celebrations, and 41% lacked gluten free (GF) snacks after school. Thirty‐six percent lacked a 504 plan, with 5% misinformed. Hand hygiene concerns included 24% using sanitizer and 10% rarely washing hands before eating. Sixty‐two percent disclosed CeD, 35% when prompted, and 3% refused, mainly 13‐year‐old males. Two percent hesitated to request GF options, and 2% consumed potentially gluten‐containing food from friends.ConclusionMany US schools provide GF accommodations under the Americans with Disabilities Act (ADA) but lack national standards. Diverse GF options and education on GF‐safe practices are crucial for GFD adherence. Discrepancies in parent–child perceptions emphasize the need for better communication. Adolescents, particularly females aged 12–13 with 2+ years on a GF diet, face higher risks. Transparent family–school communication is vital for optimizing the school experience and ensuring GFD adherence. Comprehensive nationwide school training is essential for celiac patients' well‐being.
Strategic Development of a Larynx and Trachea Transplantation Program: The Mayo Clinic Arizona Experience
Zacharias, Stephanie R. C. , Grandjean, Danielle, Stearns, Elizabeth, Mour, Girish , Mour, Girish K , Lott, David G.

Clinical Transplantation | March 11, 2025 | Volume: 39 | Issue: 3 | Pages: No page available

10.1111/ctr.70126 | PMID 40062927 Get It

ABSTRACTMedical advances have enabled the realization of vascularized composite allografts and to date have demonstrated reasonably successful graft survival rates. Larynx and Trachea Transplantation (LT) has long been contemplated as a therapeutic option for severe laryngeal trauma and patients following total laryngectomy. Progress has been limited most likely due to lack of awareness as an option, technical and surgical expertise, limited transplant centers worldwide, need for multidisciplinary engagement from hospital leadership, Otolaryngology, and transplant medicine to build a successful program. As one of the first programs to exist in the United States, we have had to create new pathways, develop new workflows, work with numerous regulatory bodies, educate many people about the need for an LT, and learn many lessons along the way. The objectives of this paper are to help others navigate the complexities of creating a new LT transplant program so that this important treatment option may become more available to patients worldwide. We will provide a checklist for developing an LT program and discuss our experiences with the strategic development of an LT transplant program in an academic medical institution.
Buprenorphine's Effect on the Human Immune System and Inflammation
Shin, Samuel D. , Branning, Rachel, McGinnis, Michele , Shin, Alexandra , Ho, Ming‐Fen , Oesterle, Tyler , Oesterle, Tyler S , McGinnis, Michele T , Ho, Ming-Fen , Shin, Samuel D. , Branning, Rachel , Karpyak, Victor M.

Clinical and Translational Science | March 11, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1111/cts.70180 | PMID 40065582 Get It

ABSTRACTOpioid use disorder is a persistent epidemic despite several FDA‐approved medications for its treatment. While the pathogenesis of opioid use disorder has been classically attributed to dopamine pathways in the brain, there is emerging evidence and interest surrounding the role of inflammation and inflammatory signaling in its development and treatment. Buprenorphine has become the most prescribed medication for opioid use disorder, largely due to its ease of access and tolerability. This review aimed to better characterize contemporary knowledge of how buprenorphine modulates the human immune system and inflammatory functions in this population. A comprehensive review was conducted using 11 key databases, including Embase, MEDLINE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov. This review captured 8177 records, and 14 studies were ultimately selected for inclusion and discussion in this review. Notably, all 14 clinical studies evaluated buprenorphine's effect on the peripheral immune system, and the majority of the studies supported the notion that initiation and maintenance of buprenorphine restore immune suppression caused by opioid use disorder. In addition, we discuss how recent and ongoing work utilizing advanced imaging and cellular technologies is advancing the understanding of how buprenorphine affects the immune and inflammatory signaling in the brain.
Strengthening Discovery and Application of Artificial Intelligence in Anesthesiology: A Report from the Anesthesia Research Council
Lonsdale, Hannah , Burns, Michael , Epstein, Richard H. , Hofer, Ira , Tighe, Patrick , Delgado, J. Arias , Kor, Daryl J. , MacKay, Emily J. , Rashidi, Parisa , Wanderer, Jonathan P. , Hofer, Ira S , Tighe, Patrick J , Gálvez Delgado, Julia A , McCormick, Patrick J

Anesthesiology | March 11, 2025 | Volume: 142 | Issue: 4 | Pages: 599-610

10.1097/aln.0000000000005326 | PMID 40067037 Get It

Interest in the potential applications of artificial intelligence in medicine, anesthesiology, and the world at large has never been higher. The Anesthesia Research Council steering committee formed an anesthesiologist artificial intelligence expert workgroup charged with evaluating the current state of artificial intelligence in anesthesiology, providing examples of future artificial intelligence applications and identifying barriers to artificial intelligence progress. The workgroup’s findings are summarized here, starting with a brief introduction to artificial intelligence for clinicians, followed by overviews of current and anticipated artificial intelligence–focused research and applications in anesthesiology. Anesthesiology’s progress in artificial intelligence is compared to that of other medical specialties, and barriers to artificial intelligence development and implementation in our specialty are discussed. The workgroup’s recommendations address stakeholders in policymaking, research, development, implementation, training, and use of artificial intelligence–based tools for perioperative care.
Pathological staging predicts survival more accurately than clinical staging in locally advanced rectal cancer following total neoadjuvant therapy
Ng, Jyi Cheng , Sassun, Richard , Sileo, Annaclara , Perry, William , Mathis, Kellie L. , Larson, David W. , Larson, David W , Cheng, Jyi Ng , Perry, William R , Sassun, Richard

British Journal of Surgery | March 11, 2025 | Volume: 112 | Issue: 3 | Pages: No page available

10.1093/bjs/znaf034 | PMID 40067085 Get It

Virtual reality for menopause symptom management: opportunities, challenges, and next steps
Safwan, Nancy , Suchak, Karisma , Liran, Omer , Kingsberg, Sheryl A. , Spiegel, Brennan , Spiegel, Brennan , Safwan, Nancy , Shufelt, Chrisandra , Faubion, Stephanie S.

Menopause | March 11, 2025 | Volume: 32 | Issue: 5 | Pages: 475-480

10.1097/gme.0000000000002529 | PMID 40067758 Get It

Importance and Objective: Menopause is the natural cessation of ovarian function, typically occurring at a mean age of 52 years in the United States. Vasomotor symptoms (VMS; hot flashes and night sweats) affect over 75% of midlife women and typically last 7 to 9 years, with only 54% seeking medical attention. Although hormone therapy is the most effective treatment for VMS, <4% of women currently use it, primarily due to safety concerns. There is evidence that cognitive behavioral therapy (CBT) is an effective management strategy for VMS. Virtual reality (VR) has shown promise in delivering an immersive form of CBT for various medical conditions, including acute and chronic pain, sleep, and mood disorders, potentially overcoming barriers such as access and cost while improving quality of life. This narrative review aims to summarize the existing literature on VR for managing menopause symptoms. Methods: A comprehensive literature review was conducted through PubMed and Medline databases. The search focused on keyword combinations related to VR, artificial intelligence, and menopause symptoms. Discussion and Conclusion: The search yielded one study specifically targeting symptoms related to menopause. A pilot study (n = 42) evaluating an immersive VR and artificial intelligence intervention based on CBT and mindfulness techniques for managing hot flashes in women with breast or ovarian cancer demonstrated a significant reduction in frequency of hot flashes ( P < 0.01) and improvements in sleep quality, mood, anxiety, stress, and overall quality of life. However, these women experienced hot flashes that might have been associated with their cancer diagnosis or treatment rather than relating specifically to menopause, potentially limiting the generalizability of the findings to women with menopause symptoms. Although VR has shown effectiveness in delivering CBT for other conditions, there remains a significant gap in research on its specific use for menopause-related symptoms.